[免疫检查点抑制剂治疗的胃肠道副作用的诊断和治疗]
Benjámin György Klément1, Kamilla Németh2, Borbála Székely1
1Mellkasi és Hasüregi Daganatok és Klinikai Farmakológiai Osztály, Országos Onkológiai Intézet, Budapest, Hungary. klement.gyorgy@oncol.hu.
Magyar onkologia
|December 12, 2025
概括
免疫疗法可能会导致严重的胃肠道副作用,如腹和结肠炎. 早期诊断和用皮质类固醇或生物药物治疗对于管理这些不良事件至关重要.
科学领域:
- 胃肠病学 胃肠病学
- 免疫学 免疫学 免疫学
- 在瘤学瘤学.
背景情况:
- 免疫治疗的使用不断扩大,导致胃肠道 (GI) 的不良事件增加.
- 这些副作用可以显著损害患者的生活质量,并带来危及生命的风险.
研究的目的:
- 为免疫疗法诱导的胃肠道副作用提供诊断和治疗策略的全面概述.
- 帮助临床医生将这些副作用与其他原因区分开来,并优化患者管理.
主要方法:
- 对与免疫疗法相关的常见和不太常见的胃肠道表现的审查.
- 分析当前的诊断方法,强调排除替代病因.
- 评估既定和新兴的治疗干预措施,包括皮质类固醇和生物药物.
主要成果:
- 常见的副作用包括腹,大肠炎,肝炎和胰腺炎.
- 不太频繁的表现包括上部消化道和类似于腹腔疾病的表现.
- 皮质类固醇是治疗的主要支柱,用于耐火病例的生物药物.
结论:
- 及时识别和管理胃肠道副作用对于患者的治疗结果至关重要.
- 一种系统的诊断方法和定制的治疗策略是必不可少的.
- 了解这些不良事件可以提高免疫治疗的安全应用.
相关概念视频
Tumor Immunotherapy
1.7K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.7K
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
459
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
459
Inflammatory Bowel Disease IV: Pharmacological Management
445
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
445
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
614
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
614
Drugs for Treatment of Ulcerative Colitis in IBD
424
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
424
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
408
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
408


